# Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma

> **NCT02784015** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 41 (estimated)

## Conditions studied

- Unresectable Localized Soft Tissue Sarcoma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Ifosfamide
- **DRUG:** Carboplatin
- **RADIATION:** Radiotherapy
- **DRUG:** Thiotepa
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT02784015
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2020-05
- **Final completion:** 2023-05
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02784015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02784015, "Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02784015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*